scholarly journals Medical management of benign prostatic hyperplasia: Results from a population-based study

2016 ◽  
Vol 10 (1-2) ◽  
pp. 55 ◽  
Author(s):  
Mohamed Bishr ◽  
Katharina Boehm ◽  
Vincent Trudeau ◽  
Zhe Tian ◽  
Paolo Dell’Oglio ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Medical Treatment ◽  
Medical Management ◽  
Population Based ◽  
Prostatic Hyperplasia ◽  
Categorical Variables ◽  
Chi Square ◽  
Alpha Blockers

<p><strong>Introduction:</strong> In men with bothersome lower urinary tract symptoms (LUTS), medical treatment usually represents the first line. We examined the patterns of medical management of benign prostatic hyperplasia (BPH) in the Montreal metropolitan area, within the context of a case control study focusing on incident prostate cancer.</p><p><strong>Methods</strong>: Cases were 1933 men with incident prostate cancer. Population controls included 1994 age-matched men. In-person interviews collected sociodemographic characteristics and medical history, including BPH diagnosis, its duration, and type of medical treatment received. Baseline characteristics were compared by the chi-square likelihood test for categorical variables and by the students t-test for continuously coded variables.</p><p><strong>Results:</strong> Overall, 1120 participants had history of BPH, of those 53.7% received medical treatment for BPH. Individuals with medically treated BPH, compared to individuals with medically untreated BPH, were older at index date [mean: 66.9 vs. 64.9 years, p˂0.001] and at diagnosis of BPH [mean: 62.3 vs. 60.3 years, p˂0.001]. They also had a longer duration of BPH-history [mean: 4.7 vs. 4.0 years, p=0.02]. Regarding medical treatment, monotherapy was more often used than combination therapy [87.6% vs. 12.4%, p˂0.001]. Alpha-blockers (69.9%) were most commonly used as monotherapy, followed by 5alpha-reductase inhibitors (5ARIs) (26.6%). Alpha-blockers plus 5ARIs were the most common combination therapy (97.3%).</p><p><strong>Conclusions:</strong> Despite evidence from randomized, controlled trials for better efficacy with use of combination therapy, monotherapy consisting of alpha-blockers or 5ARI, in that order, is most frequently used. Additionally, 5ARI use was more common than previously reported (27% vs. 15%).</p>

scholarly journals The association of new-onset diabetes mellitus and medical therapy for benign prostatic hyperplasia: A population-based study

2021 ◽  
Vol 15 (8) ◽  
pp. 240-6
Author(s):  
Jeannette Johnstone ◽  
Avril Lusty ◽  
Mina Tohidi ◽  
Marlo Whitehead ◽  
Joan Tranmer ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Medical Management ◽  
Population Based ◽  
Prostatic Hyperplasia ◽  
Increased Risk ◽  
New Diagnosis ◽  
New Onset Diabetes Mellitus ◽  
New Onset

Introduction: Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms are highly prevalent in the aging male. Similarly, the prevalence of metabolic syndrome is increasing worldwide, with mounting evidence that these two common conditions share more than age as a predisposing factor. The objective of this study was to determine if medical management of BPH is associated with an increased risk of new-onset diabetes mellitus (DM) in routine care. Methods: This population-based, retrospective cohort study expands on a parent study of linked administrative databases identifying patients diagnosed and treated for BPH between 2005 and 2015. The primary outcome of this secondary analysis was a new diagnosis of DM after the index date of BPH diagnosis. Covariates included age, dyslipidemia, hypertension, and vascular diseases. A Cox proportional hazards regression model was used for inferential statistical analysis. Results: A total 129 223 men were identified with a BPH diagnosis and no prior history of DM. Of those men, 6390 (5%) were exposed to 5-alpha-reductase inhibitor (5-ARI), 39 592 (31%) exposed to alpha-blocker (AB), and 30 545 (24%) exposed to combination therapy. Compared to those men with no BPH medication use, those exposed to drugs had an increased risk of new DM. Men treated with combination therapy of 5-ARI and AB (hazard ratio [HR] 1.30, 95% confidence interval [CI] 1.25–1.35), 5-ARI monotherapy (HR 1.25, 95% CI 1.17–1.34), or AB monotherapy (HR 1.17, 95% CI 1.13–1.22) all were at higher risk of new DM diagnosis after adjusting for important covariates. When calculating the risk of a new diabetes diagnosis measured from the start of drug exposure, men treated with 5-ARIs had an increased risk of DM compared to AB monotherapy as the reference, with HR 1.12 (95% CI 1.03–1.21) for 5-ARI monotherapy and HR 1.20 (95% CI 1.14–1.25) for combination therapy. Conclusions: In this large, long-term, retrospective study of men with a BPH diagnosis in routine practice, the risk of a new diagnosis of DM was greater in patients receiving medical management compared to controls. This modest but significant increased risk was highest in men treated with any 5-ARIs, in combination as well as monotherapy, compared to the ABs.

scholarly journals MSR1 variants and the risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China

2007 ◽  
Vol 28 (12) ◽  
pp. 2530-2536 ◽  
Author(s):  
A. W. Hsing ◽  
L. C. Sakoda ◽  
J. Chen ◽  
A. P. Chokkalingam ◽  
I. Sesterhenn ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Population Based ◽  
Prostatic Hyperplasia ◽  
Population Based Study

scholarly journals CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: A population-based study in China

2003 ◽  
Vol 107 (2) ◽  
pp. 271-275 ◽  
Author(s):  
M. Patricia Madigan ◽  
Yu-Tang Gao ◽  
Jie Deng ◽  
Ruth M. Pfeiffer ◽  
Bao-Li Chang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Population Based ◽  
Prostatic Hyperplasia ◽  
Population Based Study

Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?

2013 ◽  
Vol 23 (1) ◽  
pp. 2-4 ◽  
Author(s):  
Stacy Loeb ◽  
Angela Gupta ◽  
Lia Losonczy ◽  
Jeffrey Tosoian ◽  
Patrick C. Walsh
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Prostatic Hyperplasia ◽  
Alpha Blockers

scholarly journals Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

2019 ◽  
Vol 8 (5) ◽  
pp. 2514-2523 ◽  
Author(s):  
Yu‐Jui Kuo ◽  
Fung‐Chang Sung ◽  
Po‐Fan Hsieh ◽  
Hui‐Ping Chang ◽  
Kun‐Ling Wu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cohort Study ◽  
Benign Prostatic Hyperplasia ◽  
Cancer Risk ◽  
Prostate Cancer Risk ◽  
Population Based ◽  
Prostatic Hyperplasia

scholarly journals Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia

2017 ◽  
pp. E200-E210
Author(s):  
Deying Kang ◽  
Caoyang Hu ◽  
Yanyan Fu ◽  
Dongwen Wang
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Combination Therapy ◽  
Reductase Inhibitor ◽  
Intervention Group ◽  
Prostatic Hyperplasia ◽  
Control Group ◽  
Controlled Trials ◽  
Alpha Blockers ◽  
Randomized Controlled ◽  
Search Terms

Purpose: This study compared the efficacy of an α-blocker monotherapy alone with a combination of α-blocker plus 5α-reductase in treatment of benign prostatic hyperplasia (BPH). Methods: Medline (PubMed), EMBASE, CENTRAL (Cochrane databases) and Google Scholar were searched until May 2015 using the following search terms: ([α-blocker] AND 5α-reductase inhibitor) AND benign prostatic hyperplasia; and benign prostatic hyperplasia AND (adrenergic alpha blockers OR 5 alpha reductase inhibitor). Randomized controlled trials (RCTs) that included men with a clinical diagnosis of BPH were included. Eligible studies had to have an intervention group that received combination therapy (5α reductase inhibitor plus α-blocker) and a control group that received only α-blocker. Quality assessment and sensitivity analysis were performed. Results: Six studies were included. Combination therapy was found to significantly reduce urinary retention incidence rate (OR=0.286, 95%CI: 0.199 - 0.412, P

1438: Benign Prostatic Hyperplasia Outcomes 12 Months after Initiating Medical Management: An Analysis of Managed Care Data

2006 ◽  
Vol 175 (4S) ◽  
pp. 464-465
Author(s):  
Michael J. Naslund ◽  
Muta M. Issa ◽  
Libby Black ◽  
Michael Eaddy ◽  
Manan Shah
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Managed Care ◽  
Medical Management ◽  
Prostatic Hyperplasia

468: Polymorphic CA Repeats in IGF-I Gene is a Common Genetic Modifier in the Etiology of Prostate Cancer and Benign Prostatic Hyperplasia

2004 ◽  
Vol 171 (4S) ◽  
pp. 125-125
Author(s):  
Lizhong Wang ◽  
Kazunari Sato ◽  
Norihiko Tsuchiya ◽  
Chikara Ohyama ◽  
Shigeru Satoh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostatic Hyperplasia ◽  
Genetic Modifier ◽  
Prostatic Hyperplasia ◽  
Igf I ◽  
I Gene
Sign in / Sign up

Export Citation Format

Share Document